
Please try another search
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase II clinical trials for the treatment of dry eye disease; in Phase II clinical trial to treat neuropathic corneal pain; and is in preclinical trial to treat allergic conjunctivitis and uveitis. The company is also developing OK-201 for the treatment acute and chronic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
Name | Age | Since | Title |
---|---|---|---|
Mark Milner | - | 2024 | Member of Scientific Advisory Board |
Anat Galor | - | 2024 | Member of Scientific Advisory Board |
John Patrick Brancaccio | 76 | 2020 | Independent Non-Executive Director |
Gabriele Marco Antonio Cerrone | 53 | 2021 | Non-Executive Chairman |
Willy Jules Simon | 74 | 2015 | Senior Independent Non-Executive Director |
Bernard F. Denoyer | 78 | 2021 | Independent Non-Executive Director |
Gary S. Jacob | 78 | 2021 | CEO & Executive Director |
Jay S. Pepose | 69 | 2023 | Member of Scientific Advisory Board |
Napoleone Ferrara | 68 | 2020 | Member of Scientific Advisory Board |
Pedram Hamrah | - | - | Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review